Therefore, they explored SL-401 (DT388-IL3) and SL-501 (DT388-IL3 [K116W]) as potential therapeutic options in TKI-resistant CML cases [48]. Here, IL3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.